Swiss Malaria Group (SMG)


The Swiss Malaria Group (SMG) gathers all Swiss-based institutions active nationally and internationally in the fight against malaria. The 16 members’ organizations from the public, private, academic and non-for-profit sectors coordinate their efforts in order to engaging Swiss technical expertise, opinion makers and the general public to provide Swiss leadership against malaria at global and national levels, strengthen research and innovation by Swiss actors and fight malaria on the ground in all affected settings.

Pays/région Thème Période Budget
Monde entier
Santé
Paludisme
Maladies infectieuses
Système de santé primaire
01.01.2020 - 31.12.2023
CHF  520’000
Contexte Despite the great success of malaria-deaths being reduced by half globally since 2000, still 453’000 people die from malaria every year and 2017 data suggest that the decline in mortality has come to a halt. Malaria continues to affect approximately 200 million people annually and traps them in poverty without any significant progress over the last years. Swiss academia, industry, public sector institutions and non-governmental organisations play a central role in the global fight against malaria. Switzerland is an innovation hub for malaria control and elimination products and strategies. The Swiss Malaria Group (SMG) brings together 16 Swiss-based institutions for a malaria-free world. It covers the whole intervention chain, from research and innovation to large-scale implementation and advocacy on the ground. Swiss actors are engaged in the research and development of improved medicines, diagnostics, vaccines, bed nets, integrated vector control methods, and insecticides. Swiss Malaria Group members advocate for strong health systems and are raising awareness on a global scale to achieve the goals of ending malaria. In this phase SDC will invite the Group to broaden its scope, consider inter-sectorial interventions and address other global health challenges.
Objectifs Increase and sustain Swiss commitment to end malaria.
Groupes cibles

People in malaria endemic countries benefitting from increased investments into malaria control and elimination efforts. 

Organisations in Switzerland whose activities rely on malaria-related funding and which benefit from technical exchanges.

Effets à moyen terme

1. Network and Organizational Development: SMG functions effectively and visibly as a multi stakeholder partnership, while leveraging networking opportunities for members.

2.  Advocacy within Switzerland and in collaboration with international organizations: Increasing political commitment to support Swiss actors in their role in the fight against malaria.

3. Awareness and Public relations: Increasing awareness about malaria and its relevance for Switzerland and global development amongst the Swiss public.

4. Technical exchange: Sharing knowledge and expertise among members for more effective and efficient actions. 

Résultats

Principaux résultats attendus:  

-    Effective, responsive and sustainably resourced organisational structure operating as a multistakeholder network;

-    Collaboration with relevant organisations to highlight the comparative advantage of Swiss commitment for Global Health by tackling malaria under the UN Sustainable Development Goals;

-    The advocacy strategy and according indicators are refined;

-    A yearly campaign is targeting the Swiss public and is successfully covered in Swiss media;

-    SMG members have learned from other members and shared best practice;

-    Knowledge sharing activities take place: technical exchange/ mini symposiums/ parallel sessions.


Principaux résultats antérieurs:  

-    Annual presence with events (World Malaria Day, Bern Malaria Declaration) in German, French and Italian speaking parts of Switzerland targeting the broader public (music/photo exhibition/art installation)

-    Leverage on the parliamentary level (Formation of the Swiss Parliamentary Group on Global Health) involvement of federal and cantonal politicians/ policy makers

-    Active involvement and collaboration with international actors based in Switzerland (WHO, RBM, GF, IFRC)

-    National media outreach in German, French and Italian speaking part of Switzerland


Direction/office fédéral responsable DDC
Crédit Coopération au développement
Partenaire de projet Partenaire contractuel
Organisation suisse à but non lucratif
  • Autre organisation suisse non-profit


Autres partenaires
World Health Organization, Roll Back Malaria, Global Fund
Coordination avec d'autres projets et acteurs Novartis Pharma, Novartis Foundation, Syngenta, Biovision, Medicus Mundi Switzerland, Swiss Red Cross, Solidarmed, Medicines for Malaria Venture (MMV), Foundation for Innovative New Diagnostics (FIND), Swiss Tropical and Public Health, Centre Hospitalier Universitaire Vaudois.
Budget Phase en cours Budget de la Suisse CHF    520’000 Budget suisse déjà attribué CHF    240’000
Phases du projet Phase 99 01.01.2024 - 31.12.2025   (Active) Phase 2 01.01.2020 - 31.12.2023   (Phase en cours) Phase 1 01.07.2014 - 31.12.2019   (Completed)